Guidelines

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics — Update 2019

Claus Garbe a,*, Teresa Amaral a,b, Ketty Peris c,d, Axel Hauschild e, Petr Arenberger f, Lars Bastholt g, Veronique Bataille h, Veronique del Marmol i, Brigitte Dréno j, Maria Concetta Fargnoli k, Jean-Jacques Grob l, Christoph Höller m, Roland Kaufmann n, Aimilos Lallas o, Celeste Lebbe p, Josep Malvehy q, Mark Middleton r, David Moreno-Ramirez s, Giovanni Pellacani t, Philippe Saiag u, Alexander J. Stratigos v, Ricardo Vieira w, Iris Zalaudek x, Alexander M.M. Eggermont y On behalf of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)

DOI of original article: https://doi.org/10.1016/j.ejca.2019.11.015.
* Corresponding author: Center for Dermatooncology, Department of Dermatology, Eberhard Karls University, Tuebingen, Germany. Fax: +49 7071 29 5187. E-mail address: claus.garbe@med.uni-tuebingen.de (C. Garbe).

https://doi.org/10.1016/j.ejca.2019.11.014

0959-8049/ © 2019 Published by Elsevier Ltd.

Please cite this article as: Garbe C et al., European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics — Update 2019, European Journal of Cancer, https://doi.org/10.1016/j.ejca.2019.11.014
KEYWORDS
Cutaneous melanoma; Primary diagnosis; AJCC classification; Dermatoscopy; Sequential digital dermatoscopy; Total body photography; Confocal reflectance microscopy; Imaging diagnostics; Mutation testing; Follow-up examinations

Abstract  Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts’ experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.

© 2019 Published by Elsevier Ltd.

1. Introduction

1.1. Societies in charge

This guideline was developed on behalf of the European Dermatology Forum (EDF). The European Association of Dermato-Oncology (EADO) coordinated the authors’ contributions as part of its Guideline Program in Oncology (GPO) under the leadership of Claus Garbe, Tübingen (first author). Alexander Eggermont (senior author) was responsible for the collaboration with the European Organization for Research and Treatment of Cancer (EORTC) to ensure the interdisciplinary quality of the guideline.

1.2. Disclaimer

Medicine is subject to a continuous development process. Therefore, all statements, in particular on diagnostic and therapeutic procedures, can only correspond to the scientific knowledge current at the time of printing of this guideline. The attending physician invoking these guideline recommendations must take into account scientific progress since the publication of the guideline. In the selection and dosage of the drugs, attention was paid to compliance with the therapeutic recommendations given. Nevertheless, users are requested to use package inserts and technical information from the manufacturers as a backup, and in case of doubt, consult a specialist. The user remains responsible for all diagnostic and therapeutic applications, drugs, and doses.

1.3. Scope

This guideline has been written to assist the clinician in the diagnosis and follow-up of melanoma. Recent diagnostic strategies have been included in this
<table>
<thead>
<tr>
<th>Question</th>
<th>Step 1 (Level 1)</th>
<th>Step 2 (Level 2)</th>
<th>Step 3 (Level 3)</th>
<th>Step 4 (Level 4)</th>
<th>Step 5 (Level 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How common is the problem?</strong></td>
<td>Local and current random sample surveys (or censuses)</td>
<td>Systematic review of surveys that allow matching to local circumstances</td>
<td>Local non-random sample</td>
<td>Case-series</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>Is this diagnostic or monitoring test accurate?</strong> (Diagnosis)</td>
<td>Systematic review of cross-sectional studies with the consistently applied reference standard and blinding</td>
<td>Individual cross-sectional studies with the consistently applied reference standard and blinding</td>
<td>Non-consecutive studies, or studies without the consistently applied reference standards</td>
<td>Case-control studies, or poor or non-independent reference standard</td>
<td>Mechanism-based reasoning</td>
</tr>
<tr>
<td><strong>What will happen if we do not add a therapy?</strong> (Prognosis)</td>
<td>Systematic review of inception cohort studies</td>
<td>Inception cohort studies</td>
<td>Cohort study or control arm of randomised trial</td>
<td>Case-series or case-control studies, or poor-quality prognostic cohort study</td>
<td>n/a</td>
</tr>
<tr>
<td><strong>Does this intervention help?</strong> (Treatment Benefits)</td>
<td>Systematic review of randomised trials or n-of-1 trials</td>
<td>Randomised trial or observational study with dramatic effect</td>
<td>Non-randomised controlled cohort/follow-up study</td>
<td>Case-series, case-control studies, or historically controlled studies</td>
<td>Mechanism-based reasoning</td>
</tr>
<tr>
<td><strong>What are the COMMON harms?</strong> (Treatment Harms)</td>
<td>Systematic review of randomised trials, systematic review of nested case-control studies, n-of-1 trial with the patient you are raising the question about, or observational study with dramatic effect</td>
<td>Individually randomised trial or (exceptionally) observational study with dramatic effect</td>
<td>Non-randomised controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out common harm. (For long-term harms, the duration of follow up must be sufficient.)</td>
<td>Case-series, case-control, or historically controlled studies</td>
<td>Mechanism-based reasoning</td>
</tr>
<tr>
<td><strong>What are the RARE harms?</strong> (Treatment Harms)</td>
<td>Systematic review of randomised trials or n-of-1 trial</td>
<td>Randomised trial or (exceptionally) observational study with dramatic effect</td>
<td>Non-randomised controlled cohort/follow-up study</td>
<td>Case-series, case-control, or historically controlled studies</td>
<td>Mechanism-based reasoning</td>
</tr>
<tr>
<td><strong>Is this (early detection) test worthwhile?</strong> (Screening)</td>
<td>Systematic review of randomised trials</td>
<td>Randomised trial</td>
<td>Non-randomised controlled cohort/follow-up study</td>
<td>Case-series, case-control, or historically controlled studies</td>
<td>Mechanism-based reasoning</td>
</tr>
</tbody>
</table>

---

* Level may be graded down on the basis of study quality, imprecision, indirectness (study PICO does not match questions PICO), because of inconsistency between studies, or because the absolute effect size is very small; Level may be graded up if there is large or very large effect size.

* As always, a systematic review is generally better than an individual study.
4 C. Garbe et al. / European Journal of Cancer xxx (xxxx) xxx

guideline. Special emphasis has been placed on imaging diagnostics and follow-up examinations.

1.4. Target population

These two parts of the melanoma guideline contain recommendations for the diagnosis, follow up, and treatment of patients with melanoma. The guideline is addressed to the attending physicians and the medical nursing staff. An attempt has been made to write the guideline in a way that is easy to understand so that patients can also understand the recommendations.

1.5. Principles of methodology

The literature search was carried out by the authors using PubMed, and only articles published until September 2019 were included. Search strings were used, which cannot all be listed here. In principle, the search strings are constructed in such a way that the search is primarily carried out in the titles of the publication, e.g. melanoma [ti] AND (radiotherapy [ti] OR irradiation [ti] OR stereotactic [ti]).

All diagnostic and treatment recommendations summarised in specific tables are evaluated on the basis of evidence-based data or formulated as expert consensus when there is insufficient evidence. The methodology of these updated guidelines is based on the standards of the AGREE II instrument. The levels of evidence are graded according to the Oxford classification (Table 1) [1]. The degree of recommendation is also classified (Table 2).

The source guideline for guideline adaptation of recommendations is the German S3 guideline on malignant melanoma in the version from 2013 and the consultation version of 2019 [2,3].

1.6. Financing

The authors did this work on a voluntary basis and did not receive any honorarium. Travel costs for participation in Consensus Conferences were reimbursed in part by EADO.

2. Definition

Melanoma is a malignant tumor that arises from melanocytes and primarily involves the skin. Melanomas can also arise in the eye (uvea, conjunctiva, and ciliary body), meninges, and on various mucosal surfaces. While melanomas are usually heavily pigmented, they can also be amelanotic. Even small tumors may have a tendency to metastasise, thus leading to a relatively unfavorable prognosis. Melanomas account for 90% of the deaths associated with cutaneous tumors. In this guideline, we concentrate on the treatment of cutaneous melanoma [4–11].

3. Epidemiology and etiology

The incidence of melanoma is increasing worldwide in white populations, especially where fair-skinned people receive excessive sun exposure [12–14]. In Europe, the incidence rate is <10–25 new melanoma cases per 100,000 inhabitants; in the USA 20–30 per 100,000; and in Australia, where very high incidence is observed, 50–60 per 100,000. In recent years, there has been a dramatic increase in incidence in people over the age of 60 and especially in men in parts of Europe, but the incidence in many parts of Europe continues to increase at all ages and are predicted to continue to increase for decades [15]. The commonest phenotypic risk factor is the skin that tends to burn in the sun, and inherited melanocortin-1 receptor (MC1R) variants are the most important underlying genotype. Individuals with high numbers of common naevi and those with large congenital naevi, multiple and/or atypical naevi (dysplastic naevi) are at greater risk, and this phenotype is also genetically determined [16–19]. The inheritance of melanoma is, in most cases, seen in people with common lower risk susceptibility genes, but 5–10% of melanomas appear in melanoma-prone families that carry high penetrance susceptibility genes [20,21]. The most important exogenous factor is exposure to UV irradiation, particularly intermittent high sun exposure [22–24].

4. Different subtypes of melanoma

Cutaneous melanoma is classified as melanoma in situ when confined within the epidermis, or invasive when atypical melanocytes progressively invade into the dermis. Subtypes of invasive melanoma are distinguished by clinical and histopathological features into four major histological subtypes: superficial spreading melanoma (SSM) (41%), followed by nodular melanoma (NM) (16%), lentigo maligna melanoma (LMM) (2.7%–14%) and acral lentigious melanoma (ALM) (1%–5% in non-Hispanic White population and higher rates in Asian or African American population) [25–29]. Of note, clinical-pathologic subtypes are not included as prognostic factors in the current 8th edition of the American Joint Committee on Cancer (AJCC) staging system for melanoma [30].
SSM begins with an intraepidermal horizontal or radial growth phase, appearing first as a macule that slowly evolves into a plaque, often with multiple colors and pale areas of regression. A characteristic histologic feature is the presence of an epidermal lateral component with the pagetoid spread of clear malignant melanocytes throughout the epidermis. Secondary nodular areas representing the vertical growth phase of the tumor can develop in the further course.

NM, in contrast, is a primarily nodular, exophytic brown-black, often eroded or bleeding tumor, which is characterised by a predominant aggressive vertical growth phase. When present, an epidermal lateral component is observed histologically within and up to three rete ridges at the maximum. NM has been associated with greater Breslow thickness, and early clinical features not conforming to the well-established warning signs of ABCD, making early detection difficult [31–33].

LMM is defined as the invasive progression of the slow-growing lentigo maligna (melanoma in situ). LMM is a distinct subtype located predominantly on the sun-damaged faces of elderly individuals [34]. LMM is characterised histologically by a lentigious proliferation of atypical melanocytes at the dermoepidermal junction, confluence, formation of nests in the dermis, and a peril follicular localization of melanocytes.

ALM has a typically subungual or palmar/plantar (volar) localization. In its initial intraepidermal phase (which may be protracted), there is irregular, poorly circumscribed pigmentation; later, a nodular region reflects the invasive growth pattern.

Desmoplastic melanoma (DM) is a rare subtype (1%–4%). It is defined as a variant of spindle cell melanoma in which the malignant cells are separated by collagen fibers or fibrous stroma [35]. According to the NCCN guidelines, the presence of pure desmoplastic melanoma (as opposed to the presence of desmoplasia with spindle cell and/or epithelioid cells) may impact the decision about diagnostic staging and treatment [36].

Amelanotic/hypomelanotic melanoma is defined as a form of melanoma with little or no pigment on macroscopic or dermoscopic evaluation, or as melanoma that lacks melanin in the cytoplasm of tumor cells on histological examination [37]. Amelanotic melanoma has been more frequently associated with the nodular and desmoplastic histological subtypes and more frequently localised on the ear, nose, and face [38].

In the updated WHO classification of skin tumors (4th edition, 2018), melanoma is classified based on the pathway concept of melanoma pathogenesis and its association with sun-exposed skin (Table 3) [29]. For melanomas arising in sun-exposed skin, further classification is based on the degree of cumulative sun damage (CSD) as assessed by the degree of solar elastosis on biopsy. Melanomas arising in sun-exposed skin include low-CSD melanoma (SSM and a subset of NM) and melanoma in chronically sun-exposed skin (LMM, desmoplastic melanoma, and a subset of NM). Melanomas arising at sun-shielded sites or without known etiological associations with UV radiation exposure include Spitz melanoma, acral melanoma, mucosal melanoma (genital, oral, sinonasal), melanoma arising in congenital naevus, melanoma arising in blue naevus, uveal melanoma, nodular, and nevoid [29]. Distinct molecular signatures have been identified in tumors at different anatomical locations and with different associations with sun exposure. Melanoma of 'low UVR exposure/CSD' is mainly located on the trunk and extremities and frequently carries a BRAF mutation, which is present in ~45% of cutaneous melanomas. Melanoma of 'high UVR exposure/CSD' is located mainly in the head and neck region and has a moderate frequency of NRAS and other RAS mutations, present

<table>
<thead>
<tr>
<th>Type of UVR exposure/CSD</th>
<th>Subtype of melanoma</th>
<th>Affected genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low-CSD melanoma</td>
<td>SSM</td>
<td>BRAF V600 E/K or NRAS, CDKN2A, TP53, SWI/SNF, TERT</td>
</tr>
<tr>
<td>High-CSD melanoma</td>
<td>LMM</td>
<td>NF1, NRAS, BRAF, CDKN2A, TP53, SWI/SNF, TERT</td>
</tr>
<tr>
<td>Low to no UVR exposure (or variable incidental)</td>
<td>Spitz melanoma</td>
<td>HRAS, ROS1, NTRK1, NTRK3, ALK, RET, MET, BRAF, CDKN2A, TERT</td>
</tr>
<tr>
<td></td>
<td>Acral melanoma</td>
<td>NRAS, KIT, NF1, SPRED1, BRAF, CCND1, ALK, ROS1, RET, NTRK1, CDKN2A, CDK4, TP53, SWI/SNF, TERT</td>
</tr>
<tr>
<td></td>
<td>Mucosal melanoma</td>
<td>GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1, EIF1AX</td>
</tr>
<tr>
<td></td>
<td>(genital, oral, sinonasal)</td>
<td>GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1, EIF1AX</td>
</tr>
<tr>
<td></td>
<td>Uveal melanoma</td>
<td>GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1, EIF1AX</td>
</tr>
<tr>
<td></td>
<td>Melanoma arising in congenital naevus</td>
<td>NRAS</td>
</tr>
<tr>
<td></td>
<td>Melanoma arising in blue naevus</td>
<td>GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1, EIF1AX</td>
</tr>
</tbody>
</table>

CSD = Cumulative sun damage.
in about 15% of cutaneous melanomas. 'Non-sun-related melanomas' are mainly located on acral and mucosal sites and carry a low frequency of 

Pediatric melanoma is addressed separately. It is classified as prepubertal (congenital and childhood) pediatric melanoma occurring before the age of 10–12 years, or post-pubertal (adolescent) pediatric melanomas in patients of 10–19 years old. WHO classification of skin tumors describes four major histopathological subtypes of pediatric melanoma: [29]

- De novo melanoma;
- Melanoma arising in a congenital naevus;
- Spitzoid tumors and melanoma;
- Conventional adult-type melanoma;

Metastatic melanoma is defined as a secondary tumor derived from a primary melanoma. It may present as microsatellite, satellite, or in-transit metastases, as nodal or distant metastases. Metastatic melanomas of unknown primary occur in about 3% of the melanoma patients.

5. 8th AJCC melanoma classification and potential new biomarkers

About 90% of melanomas are diagnosed as primary tumors without any evidence of metastasis. The tumor-specific 10-year-survival for such tumors is 95–75%. The most important histological prognostic factors for primary melanoma without metastases, as reflected in recent studies, are:

- Vertical tumor thickness (Breslow's depth) as measured on the histological specimen with an optical micrometer scale, and defined as the histologic depth of the tumor from the granular layer of the epidermis to the deepest point of invasion.
- Presence of histologically recognised ulceration. Melanoma ulceration is defined as the combination of the following features: full-thickness epidermal defect (including the absence of stratum corneum and basement membrane), evidence of host response (i.e. fibrin deposition, neutrophils), and thinning, effacement, or reactive hyperplasia of the surrounding epidermis [42].
- Mitotic rate (number of mitosis/mm²) appears as an independent prognostic factor in several population studies [43] but is no longer used for sub-classification of thin melanomas in the 8th revision of the AJCC staging system (see below) [30].
- level of invasion (Clark’s level) is no longer part of the AJCC staging system.

Prognosis is also poorer with increased age, the male sex, and truncal/head and neck tumors compared to melanomas on the limbs [44,45].

Melanomas can metastasise either by the lymphatic or the hematogenous route. About two-thirds of metastases are originally confined to the drainage area of regional lymph nodes. Regional metastases can appear as:

- Satellite metastases (defined as up to 2 cm from the primary tumor).
- In-transit metastases (located in the skin between 2 cm from the site of the primary tumor and the first draining lymph node).
- Micro-metastases in the regional lymph nodes identified via sentinel lymph node biopsy [46,47]. In contrast to macro-metastasis, micrometastasis is clinically not recognizable neither by palpation nor by imaging techniques.
- Clinically or radiologically recognizable regional lymph node metastases.

The 10-year-survival is 30–50% for patients with satellite and in-transit metastases, 69–75% for patients with lymph node micrometastasis, and 40–60% for those with clinically apparent regional lymph node metastases [48].

Distant metastases have a grim prognosis in untreated patients with a median survival of only 6–9 months, although there is considerable variation depending on aggressiveness of the individual tumor, which can be clinically defined by the number of organs involved, presence of brain metastases, and serum levels of lactate dehydrogenase (LDH, Tables 6 and 7).

In 2017, the AJCC issued the 8th TNM classification for the staging of melanoma [30]. This new system now forms the cornerstone for classifying melanomas and is summarised in Tables 4–7. This classification has been criticised, as the survival of the equivalent stage differs significantly from 7th to 8th TNM classification, and

---

Please cite this article as: Garbe C et al., European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019, European Journal of Cancer, https://doi.org/10.1016/j.ejca.2019.11.014
Table 5
N classification of the regional lymph nodes for melanoma.

<table>
<thead>
<tr>
<th>N category</th>
<th>Number of involved lymph nodes (LN)</th>
<th>Presence of in-transit, satellite, and/or microsatellite metastases</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Not assessed (not required for T1 melanoma)</td>
<td>No</td>
</tr>
<tr>
<td>N0</td>
<td>0 LN+ or any in-transit, satellite, and/or microsatellite metastasis</td>
<td>No</td>
</tr>
<tr>
<td>N1a</td>
<td>1 LN+, clinically occult</td>
<td>No</td>
</tr>
<tr>
<td>N1b</td>
<td>1 LN+, clinically detected</td>
<td>No</td>
</tr>
<tr>
<td>N1c</td>
<td>0 LN+</td>
<td>Yes</td>
</tr>
<tr>
<td>N2</td>
<td>2, 3 LN+ or any in-transit, satellite, and/or microsatellite metastasis with 1 LN+</td>
<td>No</td>
</tr>
<tr>
<td>N2a</td>
<td>2, 3 LN+, clinically occult</td>
<td>No</td>
</tr>
<tr>
<td>N2b</td>
<td>2, 3 LN+, clinically detected</td>
<td>No</td>
</tr>
<tr>
<td>N2c</td>
<td>1 LN+, clinically detected or not</td>
<td>Yes</td>
</tr>
<tr>
<td>N3</td>
<td>≥4 LN+, or any in-transit, satellite, and/or microsatellite metastasis with 2, 3 LN+</td>
<td>No</td>
</tr>
<tr>
<td>N3a</td>
<td>≥4 LN+, clinically occult</td>
<td>No</td>
</tr>
<tr>
<td>N3b</td>
<td>≥4 LN+, of which ≥ 1 clinically detected</td>
<td>No</td>
</tr>
<tr>
<td>N3c</td>
<td>≥2 LN+, clinically detected or not</td>
<td>Yes</td>
</tr>
</tbody>
</table>

LN+ denotes lymph node with melanoma deposit.

Table 6
M classification of distant metastases for melanoma.

<table>
<thead>
<tr>
<th>M category</th>
<th>Anatomic site of metastasis</th>
<th>LDH level</th>
</tr>
</thead>
<tbody>
<tr>
<td>M0</td>
<td>No evidence of distant metastasis</td>
<td>Not applicable</td>
</tr>
<tr>
<td>M1a</td>
<td>Skin, subcutaneous tissue and/or non-regional lymph node</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1a(0)</td>
<td>idem</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1a(1)</td>
<td>idem</td>
<td>Elevated</td>
</tr>
<tr>
<td>M1b</td>
<td>Lung, with or without M1a sites of metastasis</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1b(0)</td>
<td>idem</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1b(1)</td>
<td>idem</td>
<td>Elevated</td>
</tr>
<tr>
<td>M1c</td>
<td>Distant metastasis to non-CNS sites, with or without M1a or M1b sites of disease</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1c(0)</td>
<td>idem</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1c(1)</td>
<td>idem</td>
<td>Elevated</td>
</tr>
<tr>
<td>M1d</td>
<td>Distant metastasis to CNS, with or without M1a, M1b, or M1c sites of disease</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1d(0)</td>
<td>idem</td>
<td>Not recorded or unspecified</td>
</tr>
<tr>
<td>M1d(1)</td>
<td>idem</td>
<td>Elevated</td>
</tr>
</tbody>
</table>

Table 7
AJCC Pathological (pTNM) prognostic stage groups.

<table>
<thead>
<tr>
<th>T is …</th>
<th>And N is …</th>
<th>And M is …</th>
<th>Then the pathological stage group is …</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
<td>0</td>
</tr>
<tr>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>1A</td>
</tr>
<tr>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
<td>1A</td>
</tr>
<tr>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td>1B</td>
</tr>
<tr>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
<td>1A</td>
</tr>
<tr>
<td>T3a</td>
<td>N0</td>
<td>M0</td>
<td>1A</td>
</tr>
<tr>
<td>T3b</td>
<td>N0</td>
<td>M0</td>
<td>1B</td>
</tr>
<tr>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
<td>1B</td>
</tr>
<tr>
<td>T4b</td>
<td>N0</td>
<td>M0</td>
<td>1C</td>
</tr>
<tr>
<td>T0</td>
<td>N1b, N1c</td>
<td>N0</td>
<td>1B</td>
</tr>
<tr>
<td>T0</td>
<td>N2b, N2c, N3b, or N3c</td>
<td>N0</td>
<td>1B</td>
</tr>
<tr>
<td>T1a/b-T2a</td>
<td>N1a or N2a</td>
<td>N0</td>
<td>1B</td>
</tr>
<tr>
<td>T1a/b-T2a</td>
<td>N1b/c or N2b</td>
<td>N0</td>
<td>1B</td>
</tr>
<tr>
<td>T2b/T3a</td>
<td>N1a-N2b</td>
<td>M0</td>
<td>1B</td>
</tr>
<tr>
<td>T1a-T3a</td>
<td>N2c or N3a/b/c</td>
<td>M0</td>
<td>1B</td>
</tr>
<tr>
<td>T3b/T4a</td>
<td>Any N ≥ N1</td>
<td>M0</td>
<td>1C</td>
</tr>
<tr>
<td>T4b</td>
<td>N1a-N2c</td>
<td>M0</td>
<td>1C</td>
</tr>
</tbody>
</table>

Recommendation 1

Stage classification

Consensus based recommendation

GCP

The classification into prognostic stages shall be performed according to the 8th edition of the AJCC classification.

Consensus rate: 100%

6. Diagnostic approach

6.1. Clinical and dermatoscopic diagnosis

In most instances, the clinical appearance of melanoma varies according to the melanoma subtype (see above). Typical features are asymmetry of the lesion, irregular borders, variability in colors, diameter of 5 mm and more, growth of nodules, and regression within the lesion. The sensitivity of clinical diagnosis by experienced dermatologists is difficult to assess but estimated to be around 70% [49].

The clinical diagnosis by the dermatologist is based on a combination of 3 analyses of any pigmented lesion: (1) visual analysis of each lesion separately, which generally excludes non-melanocytic lesions, although melanomas may rarely mimic pigmented seborrheic keratoses. Examination with the naked eye assesses the presence of the so-called A (asymmetry), B (irregular borders), C (inhomogeneous color), and D (diameter ≥ 5 mm) criteria, which point to suspicious melanocytic lesions (ABCD rule). (2) Intra-individual comparative analysis, which is searching for the lesion that is not like the others in the same patient (ugly duckling sign) [50]. (3) Chronologic analysis of changes,
which is looking for a rapid and recent change of a given pigmented lesion (E-like evolution), at least when it can be attested by the patient or documented by comparison to previous pictures. Papular or nodular lesions may lack clinical diagnostic features. In these cases, the EFG rule, standing for Elevated Firm and Growing, is relevant for prompting excision of a potentially aggressive melanoma [51].

Dermatoscopy should be used to clarify the differential diagnosis of pigmented lesions. In general, a dermatoscopic examination should be performed. However, if it is not available without significant delay due to the lack of access to a dermatologist, the definitive diagnosis and excision should not be postponed. In order to apply this technique, training and expertise are required. A meta-analysis of 22 studies showed that when experts employed dermatoscopy, they achieved an increase in diagnostic accuracy over the clinical diagnosis alone in questionable lesions, reaching a sensitivity of 89% and a specificity of 79% [52].

Characteristic features for the diagnosis of melanoma, also called melanoma-specific criteria, include an atypical pigment network, irregular brown-black dots/globules, streaks, and pigmentation with multiple colors asymmetrically distributed. Additional criteria e.g. blue-whitish veil and polymorphic vessels, are common in invasive melanoma [53—56]. Amelanotic and featureless melanoma may represent a diagnostic challenge, although suspicion should arise when a polymorphic vascular pattern is seen or when lesions do not display any of the well-known melanocytic or non-melanocytic characteristic dermatoscopic features [57—60]. This argues for urgent excision of any growing skin lesion suspicious for a skin tumor even if it looks more like a squamous lesion than a melanoma.

The prototypical dermatoscopic progression model for LMM on the face includes four sequential patterns that are annular-granular pattern, hyperpigmented follicular openings, rhomboidal structures, and atypical pseudo-network [61,62], while the importance of additional features, such as increased vascular network and red rhomboidal structures have been linked to the development of tumor-induced neo-vascularization [63].

Finally, a parallel ridge pattern and irregular diffuse pigmentation are the main dermatoscopic features of early and invasive acral melanoma, respectively [64—68].

Dermatoscopy should be applied to all lesions and not only on clinically suspicious ones. This is because dermatoscopy has the potential to uncover the natural asymmetry of melanoma before it becomes clinically recognizable.

**Recommendation 3**

<table>
<thead>
<tr>
<th>Dermatoscopic diagnosis</th>
<th>Evidence based recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level of recommendation A</strong></td>
<td>Dermatoscopy shall be used for the assessment of pigmented and non-pigmented skin lesions. Training in dermatoscopy is mandatory.</td>
</tr>
<tr>
<td><strong>Level of evidence: 1b</strong></td>
<td>De novo literature research for nail and acral melanomas [67,69—73]</td>
</tr>
<tr>
<td><strong>Consensus rate: 100%</strong></td>
<td></td>
</tr>
</tbody>
</table>

Sequential total body photography and digital dermatoscopy significantly contribute to early melanoma detection, especially in the context of high-risk individuals. All known high-risk groups (genetic predisposition, personal melanoma history, high total nevus count, etc.), might benefit from total body photography. Sequential dermatoscopic documentation is mainly meaningful in the context of high-risk individuals with multiple atypical moles, facilitating both the detection of melanoma and the reduction of the number of unnecessary excisions [74—78].

**Recommendation 4**

<table>
<thead>
<tr>
<th>Whole-body photography</th>
<th>Evidence-based recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level of recommendation B</strong></td>
<td>Whole-body photography with sequential examinations should be used for the early detection of melanoma in high-risk patients.</td>
</tr>
<tr>
<td><strong>Level of evidence: 2b</strong></td>
<td>De novo literature research [79—81]</td>
</tr>
<tr>
<td><strong>Consensus rate: 100%</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Recommendation 5**

<table>
<thead>
<tr>
<th>Digital dermatoscopy</th>
<th>Evidence-based recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Level of recommendation B</strong></td>
<td>Sequential digital dermatoscopy can improve the early detection of melanoma and should be used in high-risk patients, with a high total nevus count.</td>
</tr>
<tr>
<td><strong>Level of evidence: 2b</strong></td>
<td>De novo literature research [82—85]</td>
</tr>
<tr>
<td><strong>Consensus rate: 100%</strong></td>
<td></td>
</tr>
</tbody>
</table>

The differential diagnosis of melanoma involves other pigmented melanocytic lesions (congenital, atypical and common melanocytic naevi), non-melanocytic pigmented lesions (seborrheic keratosis, actinic lentigo,
hemangioma, dermofibroma, and pigmented basal cell carcinoma) and other non-pigmented tumors (hemangioma, basal cell carcinoma, squamous cell carcinoma).

In addition to dermatoscopy, new non-invasive methods have been introduced in the clinical setting to increase accuracy in the diagnosis of equivocal lesions. Reflectance confocal microscopy increases diagnostic specificity in equivocal dermatoscopic melanocytic lesions both in prospective studies [86–88], and in a recent meta-analysis conducted by the Cochrane Collaboration [89]. Meta-analysis found reflectance confocal microscopy to be more accurate than dermoscopy in studies of participants with any lesion suspicious for melanoma and in participants with lesions that were more difficult to diagnose, determining an increment of specificity of 82% for RCM, compared to 42% for dermatoscopy for any lesion suspicious for melanoma, and of 86% for RCM, compared to 49% for dermatoscopy for lesions that were more difficult to diagnose, concluding that RCM may have a potential role in clinical practice, particularly for the assessment of lesions that are difficult to diagnose using visual inspection and dermatoscopy alone, where the evidence suggests that RCM may be both more sensitive and specific in comparison to dermoscopy.

This technology also allows the diagnosis of subclinical lesions as amelanotic melanoma or better distinguish the limits of the tumor [88,90].

**Recommendation 6**

<table>
<thead>
<tr>
<th>Confocal laser microscopy</th>
<th>Evidence based statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of recommendation C</td>
<td>Confocal laser microscopy can be used for further evaluation of clinically/dermatoscopic equivocal skin lesions.</td>
</tr>
<tr>
<td>Level of evidence: 2b</td>
<td>De novo literature research [86–89]</td>
</tr>
<tr>
<td>Consensus rate: 100%</td>
<td></td>
</tr>
</tbody>
</table>

6.2. Histopathologic diagnosis

Whenever a suspicious skin lesion is removed, a histological examination is warranted. Difficulties in the clinical diagnosis of melanoma can also be encountered on a histologic level. The specimen should be entrusted to a dermatopathologist experienced in the interpretation of pigmented lesions. The histopathologic report should include the following information: [91]

1. Diagnosis and clinic-pathologic type (SSM, NM, LMM, ALM); when there is uncertainty about malignancy, it should be clearly stated in the report conclusion.
2. Tumor thickness in mm (Breslow depth).
3. Presence or absence of ulceration.
4. Number of mitoses per mm² (in hot spots).
5. Microsatellites (if present), defined as any discontinuous nest of intra-lymphatic metastatic cells of >0.05 mm in diameter clearly separated by normal dermis or subcutaneous fat from the invasive component of the tumor by a distance of at least 0.3 mm.

7. Lateral and deep excision margins

Besides these necessary histologic features, additional information can be provided, including:

- Growth phase (horizontal or vertical)
- Presence or absence of established regression
- Presence or absence of tumor-infiltrating lymphocytes (TIL) infiltrate preferably using the terms brisk, non-brisk, or absent
- Lymphatic emboli
- Vascular or perineural involvement

In some instances, when the histologic diagnosis is unclear, immunohistochemical stains may be helpful (i.e. S-100 protein, Melan-A, HMB45 and SOX10 for the confirmation of the melanocytic nature of the tumor, HMB45 as an additional feature of malignancy when there is an inverted positive gradient, MIB-1 as a proliferation marker).

7.1. Molecular diagnosis

Mutational analysis is required to determine the $BRAF^{V600}$ mutation status in patients with distant metastasis or non-resectable regional metastasis to identify those who are eligible to receive treatment with combined BRAF and MEK inhibitors, and in resected high-risk stage III melanoma patients in the adjuvant setting. $BRAF^{V600}$ mutation testing should be performed on metastatic tissue, either distant or regional, or on primary tumor if sampling of the metastatic tissue is not feasible. A clinically meaningful discrepancy rate in the BRAF status indeed may exist between primary and metastatic melanoma lesions [92]. Mutational analysis for BRAF of the primary lesion is not recommended for patients with cutaneous melanoma but without evidence of the disease, unless required to guide consideration of clinical trials for adjuvant therapy.

$NRAS$ mutations are identified in 15%–20% of melanoma samples and are mutually exclusive with $BRAF$ mutations, with few exceptions of patients with both $BRAF$ and $NRAS$ mutations. A positive $NRAS$ mutation also serves to reassure that a $BRAF$ mutation has not been missed. An NRAS-targeted approach for patients with NRAS mutations has so far shown limited efficacy; however, additional NRAS inhibitors and combined treatment strategies are currently under clinical investigation for these patients [93,94].

$c-KIT$-mutant melanoma represents a rare subset (1–3%), most commonly arising from mucosal, acral, and chronically sun-damaged skin. Since the positivity rate of $c-KIT$ mutations is low, acral and mucosal melanomas should initially be tested for $BRAF$ and $NRAS$
mutations, and if the wild type, additionally analyzed for c-KIT mutations. Clinical benefit has been demonstrated for c-KIT inhibitors in selected patients [95].

A recent molecular classification of melanoma included an NF1-mutant melanoma subtype. However, NF1 mutational analysis is not routinely performed since it currently lacks direct clinical implications [96,97].

Genetic profiling of melanoma tissues using next-generation panel sequencing might help in identifying genetic alterations, which can be targeted by drugs, thus assisting clinicians with clinical decision making and management. However, real-world performance data in a standardised diagnostic setting are still limited [97].

Increasing evidence has recently been reported on the clinical relevance of liquid biopsy detecting circulating tumor cells, circulating tumor DNA, and circulating RNA in peripheral blood samples that may integrate signals from all metastatic foci and can be repeated serially during the course of treatment [98]. Liquid biopsy results might be useful as predictive biomarkers enabling the determination of baseline mutational status, with a high level of concordance with tissue mutational status, assessing the suitability for targeted therapies, monitoring of treatment response and resistance to targeted therapy. Translation of liquid biopsy into clinical use for melanoma patients might be expected in the near future.

7.2. Staging examinations according to AJCC stages

Staging depends on clinical examination, and in the case of primary melanoma, on histological characteristics. Physical examination of the entire body and accessible mucosal membranes should be performed looking for second melanoma (increased risk) [99] but mostly for tumor satellites and in-transit metastases. All lymph node areas should be carefully examined with particular attention to the regional lymph node basin.

Patients with pT1a melanomas with normal physical examination and no symptoms need no further imaging nor sentinel lymph node biopsy. Ultrasound of the loco-regional lymph nodes shall be done for patients in stage IB and higher. A recent Cochrane meta-analysis showed that its use in primary staging had a sensitivity of 60% and specificity of 97% [100]. The presence of lymph node metastasis can be confirmed for all clinically or radiologically suspicious lymph nodes using fine-needle aspiration cytology (FNAC) or Ultrasound-guided core needle biopsy [101–103]. Noteworthy, ultrasound shall not be considered as a substitute for sentinel lymph node biopsy.

In primary melanoma without clinically or radiologically positive lymph node, sentinel node biopsy is the most important prognostic factor in primary tumors with Breslow >1 mm (discussed below) [104–106].

Imaging aim to detect distant metastasis includes computed tomography with intravenous contrast of the thorax and abdomen or positron emission tomography scans (PET CT); brain metastasis is better detected using brain MRI with intravenous contrast than CT scan. Such workup is generally recommended in all stage III patients. However, its significance in stage III patients with micrometastasis only (N1 or 2 a) remains debatable since distant metastasis is detected in less than 2% of these patients [107]. The positivity is higher in clinically palpable lymph node and ranges from 4 to 16% [108,109]. A recent Cochrane meta-analysis estimated the sensitivity and specificity of distant workup to 30%—47% and 73%—88%, respectively [100].

The rate of positivity is much lower in stage II patients. A recent review showed a sensitivity for PET CT ranging from 0 to 67% and specificity 77–100% and concluded that it is not beneficial [110]. Such workup can, however, be considered for the poor prognosis stage IIC.

Stage IV patients need careful total body imaging using CT or PET CT and brain MRI. No routine blood test is recommended except for stage IV patients for whom plasma LDH should be assessed.

Recommendation 7

<table>
<thead>
<tr>
<th>Lymph node ultrasound in primary melanoma</th>
<th>Evidence based recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of recommendation A</td>
<td>Ultrasound of the loco-regional lymph nodes shall be done for the initial workup in all primary melanomas pT1b and higher.</td>
</tr>
<tr>
<td>Level of evidence: 2a</td>
<td>De novo literature research [100]</td>
</tr>
<tr>
<td>Consensus rate: 90%</td>
<td></td>
</tr>
</tbody>
</table>

8. Communication with the patient

When discussing a melanoma diagnosis with the patient, it is important to give tailored advice and prognostic information. Too often, the patient has already been on the internet and is extremely anxious because of frightening information they have discovered online. Many patients can be reassured that their prognosis is excellent and that the chance of recurrence is small. Clinicians should avoid saying that if the patient had come a few months later, he/she would be in a more difficult situation. Such statements are not evidence-based, as melanoma progression can be very slow, particularly for thin melanomas, and increased anxiety leads to patients viewing any other pigmented lesions as dangerous precursors. This may lead to the patient regularly asking for biopsies of healthy naevi. Ideally, all patients should be given as accurate a prognosis as possible unless they express the view that they would rather not be told. If possible, discussing melanoma diagnosis, especially of high-risk tumors or progression of the disease, should
take place with a relative as patients are often too anxious to remember many facts. Many melanoma clinics now have a clinical nurse specialist who can spend more time with patients after the delivery of bad news to help them digest this information and to answer any further questions they may have. The clinical nurse specialist also acts as a point of contact, and patients should be encouraged to contact them if they are anxious and need support. Specialised services may also be engaged if the patient has issues of loss of income while on treatment. Liaisons with community nurses and local services may need to be arranged, and clinicians should be familiar with the social circumstances of their patients. Relatives may also access counseling services in some countries.

A family history of melanoma and other cancers should be documented, and patients and their relatives may need to be referred to a cancer genetics clinic for an open discussion around genetic risk. The presence of the atypical mole syndrome phenotype also means that if the clinician looking after a patient is not a dermatologist, the patient may need alternate follow-ups between the dermatologist and the oncologist/plastic surgeon, if feasible. First-degree relatives of patients with melanoma should have regular dermatology screening, and this should be presented as an important screening opportunity.

Sun exposure following a melanoma diagnosis is a controversial area. While it is clear that patients should be safe in the sun and avoid sunburn and excessive sun exposure, too often melanoma patients are told they should avoid any future sun-exposure. This is not safe advice; it raises anxiety, is difficult to adhere to, and limits the quality of life.

9. Melanoma in pregnancy

Melanoma is the most common cancer encountered during pregnancy and represents 31% of all malignancies [111]. But while 29% of women may have a melanoma during their reproductive period, only 0.9% will have their melanoma diagnosed during pregnancy. Various epidemiological studies have looked at the effects of pregnancy on melanoma risk and conflicting results have been published. However, current evidence suggests that pregnancy does not affect melanoma risk, with over 5500 melanoma cases in females studied in a pooled analysis of 10 case–control studies [112,113]. Although anecdotal cases of aggressive melanomas during pregnancy have been reported in the past, O’Meara et al. and Lens et al. [114,115] showed that pregnancy did not affect melanoma survival in two large population-based studies in the United States and Sweden, respectively. Another large study in Norway with a median follow-up of over 10 years supported these findings as melanoma survival was comparable between pregnant women and control women [111]. So, at present, there is enough evidence showing that pregnancy does not affect melanoma risk and does not affect melanoma survival.

When discussing future pregnancies in women after the diagnosis of melanoma with favorable prognosis, there is no need to defer the pregnancy. However, the clinician will need to take age and family circumstances into account and advise the patient accordingly. In high-risk melanomas, the advice is usually to wait two years after a melanoma diagnosis as the risk of relapse is the greatest during that period, but individual factors may affect this advice [113].

In terms of the contraceptive pill (OCP) and hormone replacement (HRT), there is also no evidence that they confer an increased risk of melanoma [113,116]. A recent Finnish study suggests that caution should apply for women on HRT with unopposed progesterone, but most women receiving HRT have combined continuous or interrupted opposition of the estrogen with progesterone [117]. Women having estrogen-only HRT may have had hysterectomy and oophorectomy for various reasons, which may be a confounding factor for melanoma risk.

Sentinel node biopsies are not contraindicated in pregnancy, but the blue dye should be avoided as it carries a small risk of an allergic reaction. Technetium is safe to use. Before the introduction of adjuvant treatments, it was thought that sentinel node biopsy should be avoided in pregnant women, as it simply completed staging and offered no therapeutic advantage. However, if the patient is toward the end of their pregnancy and possibly eligible for adjuvant treatment, sentinel node biopsy should be discussed with the patient. If a lymphadenectomy is needed for palpable lymph nodes, the best timing for surgery is the third trimester or postpartum. As such, depending on gestation at diagnosis of stage III disease, it is preferable to wait, as general anesthesia can be detrimental for a developing fetus [116]. Immunotherapy and targeted therapies are usually not considered safe for the fetus, and therefore, specific agents are used only in exceptionally rare circumstances. Women in the first or second trimester are usually advised to terminate their pregnancy, as are those whose life is imminently threatened by their disease as treatment should not be delayed. Pregnant women can still have MRIs instead of CT scans for surveillance of high-risk tumors. Women should be advised to ensure the use of adequate contraception when treated with immunotherapy or targeted therapy.

10. Follow-up

10.1. General principles

Follow up after melanoma diagnosis aims the following goals:
1. Identifying recurrent disease (local, distant) at the earliest stage;
2. Offering psychosocial support;
3. Providing education on prevention, for the patient and his/her first-degree relatives;
4. Providing education of the patient and his family on skin self-examination to promote early detection of melanoma;
5. Administering and monitoring adjuvant therapy, where appropriate;
6. Improve early detection of subsequent secondary melanoma and non-melanoma skin cancers [118,119];
7. Recognise and treat cutaneous side-effects related to adjuvant or palliative treatment [120–122].

No randomised trials are currently available comparing different follow-up schemes in melanoma patients, and different follow-up schemes have been proposed on an international level [123]. An example of follow-up schedule examinations in melanoma by stage is presented in Table 8.

**Frequency and extent of follow-up:** The frequency and extent of follow-up examinations depend on the primary tumor stage and presence of additional risk factors (i.e. multiple nevi, family, and personal history of melanoma, history of sunburns, etc.) [124,125]. The following examinations are recommended:

1. Careful evaluation of reported symptoms;
2. Physical examination of the scar and surrounding skin;
3. Physical examination of the lymph nodes;
4. Total skin clinical and dermatoscopic examination, including the genitals, oral mucosa, and scalp;
5. Blood testing for LDH and S-100 [126,127].

**Table 8**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Clinical-dermatological examination</th>
<th>Lymph node sonography</th>
<th>Laboratory examination: LDH, S-100</th>
<th>CT neck, thorax, abdominal, pelvic, or PET-CT – MRI head</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 to 3</td>
<td>4 to 10</td>
<td>&gt;10</td>
<td>1 to 3</td>
</tr>
<tr>
<td>IA</td>
<td>6 m</td>
<td>12 m</td>
<td>12 m</td>
<td>–</td>
</tr>
<tr>
<td>IB-IIB</td>
<td>3–6 m</td>
<td>6 m</td>
<td>12 m</td>
<td>3–6 m</td>
</tr>
<tr>
<td>IIIC-IIIC</td>
<td>3 m</td>
<td>6 m</td>
<td>12 m</td>
<td>3–6 m</td>
</tr>
<tr>
<td>IIID</td>
<td>3 m</td>
<td>6 m</td>
<td>12 m</td>
<td>3–6 m</td>
</tr>
<tr>
<td>IV NED (resected, CR under therapy)</td>
<td>3 m</td>
<td>6 m</td>
<td>12 m</td>
<td>3–6 m</td>
</tr>
<tr>
<td>IV (M1a – M1d) (distant metastasis)</td>
<td>Individually, depends on examinations, therapy, and symptoms; otherwise staging every 12 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For patients with high-risk melanoma (resected stage IV or stage III melanoma), the timing between follow-up visits and requested radiographic imaging examinations should be discussed by a multidisciplinary team and depends on whether patients receive therapy or not.

In non-resected stage IV melanoma or patients with suspected but not verified metastases, surveillance depends on the setting:

1. In an active treatment setting, imaging and surveillance aims to assess the treatment efficacy;
2. In the setting of suspected metastatic disease, surveillance aims to assess the evolution over time;
3. In patients with distant metastases, follow-up should be discussed case by case according to the willingness of the patient and the medical considerations of the treating physician.

In a single-center prospective study of 10 years in 290 consecutive melanoma patients, it was observed that intensive monitoring was appropriate for early detection of recurrence in stage IIB, IIC, and III melanoma. In contrast to previous studies, 17.8% of recurrences were detected by the patient, 23.7% by the physician, and 56.7% by imaging tests. This increase in the number of metastases detected by imaging tests can be explained by the more frequent use of CT and MRI, which have higher sensitivity and specificity than chest X-ray [133]. In the same cohort, six-monthly CT scan of the chest, abdomen, and pelvis was a cost-effective technique for the early detection of metastases in the first 4 years of follow-up in patients with AJCC stage IIC and III melanoma, and in the first 3 years in patients with AJCC stage IIB melanoma. In addition, brain MRI was shown to be cost-effective only in the first year of follow-up in patients with AJCC stage IIC and III melanoma [134].

For patients with high-risk melanoma (resected stage IV or stage III melanoma), AJCC T1b stage and above is advisable according to the willingness of the patient and the medical considerations of the treating physician.

However, performing an ultrasound for assessing lymph node metastasis in patients with AJCC T1b stage and above is advisable according to the most recent international guidelines. In patients with stage T4b, CT, or PET, CT is suitable for the detection of metastasis. Brain MRI at T4b deserves further discussion, considering the ultimate clinical benefit in terms of management and therapeutic options for asymptomatic patients [132].
10.2. Recommendations for structured follow-up

The classical follow-up ‘rules’ are variable across Europe, ranging in frequency from 2 to 4 times per year for 5–10 years, with limited data to support the different schedules.

In stage I to II melanoma, the intent is to detect early loco-regional recurrence so that the frequency of follow-up examination is usually every 3 months for the first two to five years, whereas for the next years to 10th year period attendance every 6 months seems to be adequate. In patients with thin cutaneous melanoma (≤0.8 mm), six-monthly intervals may be sufficient and some guidelines support a limited follow up of 1 year for stage IA melanoma. However, the introduction of the new treatments (targeted and immunotherapies) may lead to a complete revision of these algorithms, in order to promote earlier detection of metastases, depending on whether or not the impact on survival was proven to be better when they are given early than later. A proposal for a structured stage-based follow-up schedule is given in Table 8.

11. Consensus-building process and participants

These guidelines originate from contributors who were involved in the development of their national guidelines. These national guidelines were elaborated by the different specialties involved in the management of melanoma patients (dermatology, medical oncology, surgical oncology, radiotherapy, pathology, and others).

These guidelines were prepared under the auspices of the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). In a first-round, medical experts who participated in their national guideline development processes were involved. In a second round, the EORTC selected experts from different specialties to contribute to these guidelines. This process was first organised in 2008/2009, and the update was developed by the same groups in 2012 and 2016. The formal recommendations were discussed and agreed upon at the consensus conference on the 23rd of September 2019 in Rome by the Guideline Group, represented by 20 European experts. Professor Claus Garbe, Tübingen, coordinated the activities of the selected experts and the final authors. These guidelines are planned to be updated at least every two years.

Conflict of interest statement

Dr. Garbe reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Neracare, grants and personal fees from BMS, personal fees from Pierre Fabre, personal fees from Philogen, grants and personal fees from Roche, grants and personal fees from Sanofi, outside the submitted work. Dr. Amaral reports personal fees and other from BMS, grants, personal fees, and others from Novartis, personal fees from Pierre Fabre, grants from Neracare, grants from Sanofi, outside the submitted work. Dr. Peris reports personal fees from Novartis, personal fees from Roche, personal fees from Sanofi, personal fees from Lilly, personal fees from Leopharma, personal fees from Pierre Fabre, personal fees from Almirall, personal fees from Celgene, outside the submitted work. Dr. Hauschild reports grants and personal fees from Amgen, grants and personal fees from MSD, grants and personal fees from MerckSerono, grants and personal fees from MSD/Merck, grants and personal fees from Philogen, grants and personal fees from Pierre Fabre, grants and personal fees from Proveuctus, grants and personal fees from Regeneron, grants and personal fees from Roche, personal fees from OncoSec, grants and personal fees from Sanofi-Genzyme, personal fees from Sun Pharma, grants and personal fees from Novartis Pharma outside the submitted work. Dr. Arenberger reports personal fees from Amgen, personal fees from MSD, personal fees from Novartis, personal fees from BMS, personal fees from Roche, outside the submitted work. Dr. Basbhoht reports grants from BMS, during the conduct of the study; personal fees from BMS, personal fees from Novartis, personal fees from Merck MSD, personal fees from Roche, personal fees from Incyte, personal fees from Bayer, outside the submitted work. Dr. Bataille reports personal fees from Novartis, personal fees from Merck MSD, outside the submitted work. Dr. del Marmol reports personal fees from MSD, from BMS, personal fees from Sanofi, grants and personal fees from ABVIE, grants from Jansen, outside the submitted work. Dr. Dréno reports grants and personal fees from...
BMS, personal fees from MSD, grants and personal fees from Roche, grants and personal fees from Fabre, grants and personal fees from Sanofi, outside the submitted work. Dr. Fargnoli reports grants and personal fees from Almirall, grants and personal fees from Leo Pharma, personal fees from Janssen, grants and personal fees from Novartis, personal fees from Lilly, grants and personal fees from Sanofi, personal fees from UCB, grants and personal fees from Abbvie, personal fees from Celgene, personal fees from Pierre Fabre, grants and personal fees from Galderma, personal fees from Mylan, personal fees from Medac Pharma, personal fees from Roche, personal fees from Sun Pharma, outside the submitted work. Dr. Grob reports personal fees from Amgen, personal fees from MSD, personal fees from Novartis, personal fees from BMS, personal fees from Roche, personal fees from Pierre Fabre, personal fees from Merck/Pfizer, outside the submitted work. Dr. Hoeller reports personal fees from Amgen, personal fees from MSD, personal fees from Novartis, personal fees from Incyte, personal fees from BMS, personal fees from Pierre Fabre, personal fees from Roche, personal fees from Sanofi, outside the submitted work. Dr. Kaufmann reports grants and personal fees from Novartis and Roche, and grants from Abbvie, Amgen, Bionteck, BMS, Celgene, Galderma, Janssen, Leo, Lilly, Merck, MSD, Pierre Fabre, Regeneron, and Wyeth, outside the submitted work. Dr. Lallas reports personal fees from Amgen, personal fees from Novartis, personal fees from BMS, grants and personal fees from Roche, personal fees from Sanofi, outside the submitted work. Dr. Lebbe reports grants and personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Novartis, personal fees from Amgen, grants and personal fees from Roche, personal fees from Avantis Medical Systems, personal fees from Pierre Fabre, personal fees from Pfizer, personal fees from Incyte, outside the submitted work. Dr. Malvehy reports personal fees from Amgen, personal fees from MSD, grants from Novartis, grants and personal fees from BMS, grants and personal fees from Roche, grants and personal fees from Almirall, personal fees from Sun Pharma, outside the submitted work. Dr. Middleton reports personal fees from Amgen, grants and personal fees from Roche, grants and personal fees from AstraZeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millennium, personal fees, non-financial support and other from Immunocore, personal fees and other from BMS, personal fees and other from Eisai, other from Pfizer, personal fees, non-financial support and other from Merck/MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, outside the submitted work. Dr. Moreno-Ramirez has nothing to disclose. Dr. Pellacani reports personal fees from Novartis, personal fees from Sanofi, grants from Novartis, instruments from 3 Gen, Vidix, Fotofinder and MAVIG GmbH, outside the submitted work. Dr. Saïag reports personal fees from Amgen, personal fees from MSD, grants and personal fees from Novartis, personal fees from Roche, personal fees from Fabre, personal fees from Regeneron, Genesis Pharma, outside the submitted work. Dr. Stratigos reports personal fees and/or research support from Novartis, Roche, BMS, Abbvie, Sanofi, Regeneron, outside the submitted work. Dr. Vieira has nothing to disclose. Dr. Zalaudek reports personal fees from Difa Cooper, personal fees from MSD, personal fees from Novartis, grants and personal fees from Roche, personal fees from Sanofi, personal fees from Almirall Hermal, personal fees from Mylan, personal fees from Sunpharma, outside the submitted work. Dr. Eggermont reports personal fees from Biocad, Biovent, BMS, CatalYm, Ellipses, GSK, Incyte, IO Biotech, ISA Pharmaceuticals, Merck GmbH, MSD, Novartis, Pfizer, Polynoma, Regeneron, Sanofi, SkylineDx, Stellas, other from RiverD, SkylineDx, Theranovir, all outside the submitted work.

References


[45] Jooos A, Collette S, Suciu S, Nijsten T, Lejune F, Kleeberg UR, et al. Superior outcome of women with stage I/II melanomas...


